AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 125 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 2.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $418,000 | -97.5% | 6,977 | -98.8% | 0.00% | -100.0% |
| Q3 2019 | $16,416,000 | -29.5% | 584,393 | -5.0% | 0.02% | -26.1% |
| Q2 2019 | $23,298,000 | -55.7% | 615,378 | -54.3% | 0.02% | -55.8% |
| Q1 2019 | $52,559,000 | +140.6% | 1,346,970 | +31.5% | 0.05% | +116.7% |
| Q4 2018 | $21,846,000 | -46.4% | 1,024,691 | -0.4% | 0.02% | -36.8% |
| Q3 2018 | $40,725,000 | +4.4% | 1,028,668 | +0.8% | 0.04% | 0.0% |
| Q2 2018 | $38,995,000 | +29.4% | 1,020,556 | +1.8% | 0.04% | +26.7% |
| Q1 2018 | $30,131,000 | +12.9% | 1,002,679 | +17.4% | 0.03% | +15.4% |
| Q4 2017 | $26,682,000 | +12.9% | 853,822 | +1.2% | 0.03% | +8.3% |
| Q3 2017 | $23,642,000 | +46.0% | 844,060 | -0.3% | 0.02% | +41.2% |
| Q2 2017 | $16,189,000 | +217.1% | 846,273 | +182.4% | 0.02% | +240.0% |
| Q1 2017 | $5,106,000 | -6.7% | 299,656 | 0.0% | 0.01% | -16.7% |
| Q4 2016 | $5,475,000 | +3.0% | 299,656 | +0.4% | 0.01% | 0.0% |
| Q3 2016 | $5,318,000 | – | 298,586 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |